Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil

Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease

(2009) Stephen C. Mathai et al.   ARTHRITIS AND RHEUMATISM

The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France

(2009) Eric Hachulla et al.   ARTHRITIS AND RHEUMATISM

Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis

(2009) Y. SCHOINDRE et al.   JOURNAL OF RHEUMATOLOGY

Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study

(2009) E. Hachulla et al.   RHEUMATOLOGY

Connective Tissue Disease–associated Pulmonary Arterial Hypertension in the Modern Treatment Era

(2008) Robin Condliffe et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients

(2008) A-L Hachulla et al.   ANNALS OF THE RHEUMATIC DISEASES

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

(2008) Nazzareno Galiè et al.   CIRCULATION

Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials

(2007) J Avouac et al.   ANNALS OF THE RHEUMATIC DISEASES